Sarah Gheuens compensation by year
AGIOS PHARMACEUTICALS Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $566,500 | $583,495 | $601,060 |
| Stock awards | $1,008,114 | $548,590 | $397,440 |
| Option awards | $614,478 | $1,068,185 | $802,008 |
| Non-equity incentive | $666,964 | $328,216 | $270,478 |
| All other | $14,103 | $15,861 | $15,694 |
| Total | $2,870,159 | $2,544,347 | $2,086,680 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: AGIOS PHARMACEUTICALS, INC. DEF 14A filed April 24, 2026, accession 0001193125-26-177086, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 24,300 | $661,446 | — |
| RSU | 12,000 | $326,640 | — |
| RSU | 11,333 | $308,484 | — |
| RSU | 8,375 | $227,968 | — |
| RSU | 4,000 | $108,880 | — |
| Option | 2,565 | — | $32.20 |
| Option | 13,755 | — | $25.01 |
| Option | 33,750 | — | $32.27 |
| Option | 43,500 | — | $33.12 |
| Option | 55,374 | — | $33.95 |
Per the Outstanding Equity Awards at Fiscal Year-End table in AGIOS PHARMACEUTICALS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
6 Form 4 lines since the FY2025 proxy (filed April 24, 2026)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-08-04 | Sale | 10b5-1 | 30,000 | $30.48 | 54,645 |
| 2026-07-01 | Exercise or conversion | 10b5-1 | 8,375 | $0.00 | 88,652 |
| 2026-07-01 | Sale | 10b5-1 | 4,007 | $37.56 | 84,645 |
| 2026-07-01 | Exercise or conversion derivative | 10b5-1 | 8,375 | $0.00 | 0 |
| 2026-06-18 | Exercise or conversion derivative | — | 3,000 | $0.00 | 9,000 |
| 2026-06-18 | Grant or award derivative | — | 3,000 | $0.00 | 3,000 |
The 6 most recent of 6 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
AGIOS PHARMACEUTICALS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Brian Goff | Chief Executive Officer | $5,370,389 |
| Krishnan Viswanadhan | Chief Corporate Development & Strategy Officer | $2,805,026 |
| Cecilia Jones | Chief Financial Officer | $2,518,222 |
| James Burns | Chief Legal Officer | $2,369,416 |
| Sarah Gheuens · this page | Chief Medical Officer, Head of Research & Development | $2,086,680 |
The full AGIOS PHARMACEUTICALS compensation record
free company briefThis page is one person within AGIOS PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order AGIOS PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are AGIOS PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat